Novanta Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 29, 2023; comparisons are to periods ended September 30, 2022. Amounts are in U.S. dollars. Novanta supplies precision technology to medical and advanced industrial OEMs through Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $221.5m | $223.0m | $670.1m | $642.5m |
| Gross profit / margin | $101.6m / 45.9% | $98.4m / 44.1% | $303.3m / 45.3% | $283.9m / 44.2% |
| Operating income | $30.3m | $28.7m | $88.8m | $76.2m |
| Net income | $21.2m | $22.5m | $60.4m | $58.8m |
| Diluted EPS | $0.59 | $0.63 | $1.68 | $1.64 |
- Cash flow: Nine-month operating cash flow was $81.1m, versus $50.2m; capital expenditures were $13.7m. Investing cash outflow was $13.7m and financing cash outflow was $92.8m, principally reflecting $82.0m of debt repayments and $10.2m of payroll taxes on vested awards.
- Liquidity and debt: Cash was $76.0m at September 29, down from $100.1m at year-end 2022. Reported debt was $352.6m, down from $435.5m; net debt was approximately $276.7m. Revolver availability was $415.6m. The company reported compliance with debt covenants: leverage ratio 1.68 against a 3.50 maximum, and fixed-charge coverage 5.03 against a 1.50 minimum.
- Margins and taxes: Q3 operating income was approximately 13.7% of revenue, compared with 12.9% a year earlier. Effective tax rates were 7.7% for Q3 and 11.2% for the nine-month period.
Material changes versus the prior comparable period
- Q3 revenue declined 0.7%; nine-month revenue increased 4.3%. Medical Solutions grew 13.7% in Q3 and 21.6% year to date, while Robotics and Automation declined 15.2% and 11.7%, respectively. The latter weakness was tied primarily to advanced industrial demand, especially microelectronics.
- Q3 medical-market demand and prior-year acquisition revenue partly offset softer advanced industrial demand. For nine months, medical-market growth drove results; medical revenue was 54% of total, compared with 48% in the prior-year period.
- Q3 gross margin improved 1.8 percentage points. Management cited factory efficiency and favorable mix; segment margins also benefited from insurance recoveries related to a 2022 supplier fire. The company received $5.0m in recoveries during the nine months and the claim was fully settled.
- Q3 net income and EPS fell despite higher operating income, primarily because net interest expense increased to $6.8m from $4.1m and foreign exchange results shifted from a $2.1m gain to a $0.4m loss. Nine-month net income increased modestly as operating improvement and lower taxes largely offset higher interest expense.
- Weighted average borrowing rates rose materially: 6.68% in Q3 versus 3.37%, and 6.12% for nine months versus 2.72%. Nine-month net interest expense was $19.9m versus $9.9m.
Outlook, commentary, risks and unusual items
- The filing provides no specific revenue or earnings guidance. Management expects operating cash flows to cover operating and capital needs for at least the next 12 months, while noting liquidity depends on business conditions and access to financing.
- Management expects 2023 capital expenditures of approximately $22m–$24m, including a significant U.K. facility buildout. It expects the 2022 restructuring program to be substantially complete by year-end 2023, with another $2.5m–$3.0m of charges anticipated. The 2020 restructuring program was substantially completed in Q3.
- Customer backlog coverage had declined from elevated levels but remained above historical averages; management expected customers to gradually shorten lead times as supply disruptions ease. Risks include supply interruptions, inflation and labor costs, weak or cyclical industrial demand, higher interest rates, foreign-exchange movements, geopolitical uncertainty, and OEM customer spending patterns.
- Restructuring, acquisition and related costs were $4.5m in Q3 and $8.2m year to date, versus $1.6m and $2.7m, respectively, in the prior periods. The nine-month restructuring accrual included $1.4m of asset impairment.
- The company said ordinary-course legal matters were not expected to have a material adverse effect, though outcomes cannot be assured. Disclosure controls were deemed effective; no material change in internal control was reported.
Investor verification priorities
- Track Robotics and Automation demand, particularly microelectronics, alongside the pace of backlog and customer lead-time normalization.
- Assess the sustainability of gross-margin improvement, separating operating efficiencies and mix from the settled, nonrecurring insurance recovery.
- Monitor interest expense, borrowing rates, debt repayments, covenant headroom and available revolver capacity.
- Reconcile operating cash-flow improvement with working-capital movements, cash taxes, incentive compensation and planned capital spending.
- Follow completion costs and expected benefits of restructuring, and confirm whether the stated additional charges and completion timetable are realized.